AngioDynamics, Inc. (ANGO)
NASDAQ: ANGO · IEX Real-Time Price · USD
6.08
+0.29 (5.01%)
At close: May 2, 2024, 4:00 PM
6.25
+0.17 (2.80%)
After-hours: May 2, 2024, 5:25 PM EDT
AngioDynamics Revenue
AngioDynamics had revenue of $324.01M in the twelve months ending February 29, 2024, down -3.19% year-over-year. Revenue in the quarter ending February 29, 2024 was $75.18M, a -6.85% decrease year-over-year. In the fiscal year ending May 31, 2023, AngioDynamics had annual revenue of $338.75M with 7.13% growth.
Revenue (ttm)
$324.01M
Revenue Growth
-3.19%
P/S Ratio
0.75
Revenue / Employee
$397,556
Employees
815
Market Cap
243.53M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
May 31, 2023 | 338.75M | 22.53M | 7.13% |
May 31, 2022 | 316.22M | 25.21M | 8.66% |
May 31, 2021 | 291.01M | 26.85M | 10.17% |
May 31, 2020 | 264.16M | -6.48M | -2.39% |
May 31, 2019 | 270.63M | 8.98M | 3.43% |
May 31, 2018 | 261.66M | -8.13M | -3.01% |
May 31, 2017 | 269.79M | -84.10M | -23.77% |
May 31, 2016 | 353.89M | -2.64M | -0.74% |
May 31, 2015 | 356.53M | 2.11M | 0.60% |
May 31, 2014 | 354.43M | 12.51M | 3.66% |
May 31, 2013 | 341.92M | 120.00M | 54.07% |
May 31, 2012 | 221.92M | 6.17M | 2.86% |
May 31, 2011 | 215.75M | -285.00K | -0.13% |
May 31, 2010 | 216.04M | 20.98M | 10.76% |
May 31, 2009 | 195.05M | 28.55M | 17.15% |
May 31, 2008 | 166.50M | 54.27M | 48.36% |
Jun 2, 2007 | 112.23M | 33.78M | 43.05% |
Jun 3, 2006 | 78.45M | 18.16M | 30.12% |
May 28, 2005 | 60.29M | 11.23M | 22.90% |
May 29, 2004 | 49.06M | 10.62M | 27.63% |
May 31, 2003 | 38.43M | 7.54M | 24.42% |
Jun 1, 2002 | 30.89M | 7.50M | 32.06% |
Jun 2, 2001 | 23.39M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Coherus BioSciences | 257.24M |
Puma Biotechnology | 235.64M |
2seventy bio | 100.39M |
AVITA Medical | 51.57M |
Foghorn Therapeutics | 34.16M |
Adlai Nortye | 5.00M |
Actinium Pharmaceuticals | 81.00K |
ANGO News
- 4 weeks ago - AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture - Business Wire
- 4 weeks ago - AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE - Business Wire
- 4 weeks ago - AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc. - Business Wire
- 6 weeks ago - AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024 - Business Wire
- 2 months ago - AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference - Business Wire
- 2 months ago - AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million - Business Wire
- 3 months ago - AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease - Business Wire
- 4 months ago - AngioDynamics stock dives after sales miss, lowered full-year outlook - Market Watch